Letrozole
ONCOLOGY
Letrozole is a aromatase Inhibitor. It is used in the treatment of breast cancer. inhibits the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization
Imatinib mesylate
ONCOLOGY
Imatinib is a tyrosine kinase inhibitor. It inhibits the activity of the Bcr-Abl tyrosine kinase (TK)
Sorafenib tosylate
ONCOLOGY
Sorafenib is a tyrosine kinase inhibitor, Angiogenesis Inhibitor and VEGF inhibitor. It inhibits multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases
Nilotinib.HCl.H2O
ONCOLOGY
Nilotinib is a tyrosine kinase inhibitor. It inhibits the ABL tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukaemia cells
Erlotinib.HCl
ONCOLOGY
Erlotinib is a tyrosine kinase inhibitor, epidermal growth factor receptor inhibitor, EGFR inhibitor and EGF receptor inhibitor. It inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal
Sunitinib malate
ONCOLOGY
Sunitinib is a multi-receptor tyrosine kinase (RTK) inhibitor. It inhibits CD117 (c-KIT) , the receptor tyrosine kinase and all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors
Gefitinib
ONCOLOGY
Gefitinib is a tyrosine kinase inhibitor. It inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme
Palbociclib
ONCOLOGY
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor or CDK4/6 inhibitor.it is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, that acts by binding to the ATP pocket with an IC50
Ibrutinib
ONCOLOGY
Ibrutinib is a burton’s tyrosine kinase inhibitor. it forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity
Lenalidomide
ONCOLOGY
Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma
Pazopanib.HCl
ONCOLOGY
Pazopanib is a multi-receptor tyrosine kinase inhibitor. It inhibits multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor
Regorafenib
ONCOLOGY
Regorafenib is a multiple receptor tyrosine kinase inhibitor. It inhibits the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAF
Dasatinib.H2O
ONCOLOGY
Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.
Dasatinib anhydrous
ONCOLOGY
Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ
VANDETANIB
ONCOLOGY
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2, and EGFR; TKI inhibition blocks angiogenesis and cellular proliferation
OSIMERTINIB
ONCOLOGY
Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of
CRIZOTINIB
ONCOLOGY
Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor.